Bli medlem
Bli medlem

Du är här


Meridian Bioscience, Inc.: Meridian Bioscience Announces the Launch of TruQuick(TM) Rapid Tests for Asia Pacific

CINCINNATI, Feb. 03, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc.
(NASDAQ:VIVO) today announced the launch of TruQuick(TM), a comprehensive
point-of-care product menu of rapid tests for the diagnosis of tropical,
infectious, sexually transmitted, respiratory, gastrointestinal, cancer, and
cardiac diseases. This product menu will enable Meridian to rapidly expand
its product portfolio of high value rapid tests for its commercial operations
in Asia Pacific and other emerging markets around the world.

TruQuick(TM) is a qualitative lateral flow chromatographic immunoassay menu of
over 60 products. TruQuick(TM) rapid tests can aid in the diagnosis of
infectious pathogens and other important acute diseases in 10 to 20 minutes
with high levels of accuracy and speed to results. Meridian understands the
clinical testing requirements in Asia and other emerging markets for speed,
sensitivity, specificity, and breadth of product line.

Lourdes Weltzien, Ph.D., President of Meridian Asia Pacific commented, "We are
excited to launch the new TruQuick(TM) brand of rapid tests for the rapidly
growing point-of-care market in the Asia Pacific region. As for other regions
of the world, Meridian will quickly introduce the TruQuick(TM) brand of
products based on regional demands and registration priorities."

Richard L. Eberly, President, Chief Commercial Officer, stated, "One of
Meridian's key strategies over the past few years has been to expand our
global commercial operations in emerging markets around the world. Meridian
has expanded operations in China, Singapore, Australia, Africa, and South
America. The product portfolio for these emerging markets is rapidly
expanding. We are delighted to add the TruQuick(TM) brand of rapid
point-of-care products to our commercial channels in these important

About Meridian Bioscience, Inc.

Meridian is a fully integrated life science company that develops,
manufactures, markets and distributes a broad range of innovative diagnostic
test kits, rare reagents, specialty biologicals and components. Utilizing a
variety of methods, our diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions, such
as infections and lead poisoning. Meridian's diagnostic products are used
outside of the human body and require little or no special equipment. The
Company's diagnostic products are designed to enhance patient well-being
while reducing the total outcome costs of health care. Meridian has strong
market positions in the areas of gastrointestinal and upper respiratory
infections and blood lead level testing. In addition, Meridian is a supplier
of rare reagents, specialty biologicals and components used by organizations
in the life science and agribio industries engaged in research and by
companies as components in the manufacture of diagnostics. The Company
markets its products and technologies to hospitals, reference laboratories,
research centers, diagnostics manufacturers and agribio companies in more
than 70 countries around the world. The Company's shares are traded on the
NASDAQ Global Select Market, symbol VIVO. Meridian's website address is

Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Meridian Bioscience, Inc. via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.